Allogene Therapeutics, Inc.

NasdaqGS:ALLO Stock Report

Market Cap: US$286.2m

Allogene Therapeutics Valuation

Is ALLO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALLO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$4.66
Fair Value
71.5% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: ALLO ($1.33) is trading below our estimate of fair value ($4.66)

Significantly Below Fair Value: ALLO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALLO?

Key metric: As ALLO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ALLO. This is calculated by dividing ALLO's market cap by their current book value.
What is ALLO's PB Ratio?
PB Ratio0.9x
BookUS$344.56m
Market CapUS$286.23m

Price to Book Ratio vs Peers

How does ALLO's PB Ratio compare to its peers?

The above table shows the PB ratio for ALLO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average22.2x
HUMA Humacyte
82.3x67.34%US$284.3m
BNTC Benitec Biopharma
3.7x43.87%US$360.2m
ABEO Abeona Therapeutics
1.7x20.57%US$272.8m
LYEL Lyell Immunopharma
1.1x-4.31%US$303.7m
ALLO Allogene Therapeutics
0.9x18.54%US$286.2m

Price-To-Book vs Peers: ALLO is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (22.2x).

Price to Book Ratio vs Industry

How does ALLO's PB Ratio compare vs other companies in the US Biotechs Industry?

54 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.4x1.69%US$155.54m
ZNTL Zentalis Pharmaceuticals
0.4x13.87%US$119.74m
XBIT XBiotech
0.5xn/aUS$80.49m
ARTV Artiva Biotherapeutics
0.5x-9.92%US$72.06m
ALLO 0.9xIndustry Avg. 2.5xNo. of Companies79PB0246810+
54 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ALLO is good value based on its Price-To-Book Ratio (0.9x) compared to the US Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is ALLO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALLO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALLO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALLO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.33
US$7.56
+468.42%
41.62%US$14.00US$1.60n/a10
Sep ’26US$1.13
US$7.56
+569.03%
41.62%US$14.00US$1.60n/a10
Aug ’26US$1.08
US$7.85
+626.85%
38.22%US$14.00US$2.50n/a10
Jul ’26US$1.18
US$8.15
+590.68%
37.42%US$14.00US$2.50n/a10
Jun ’26US$1.17
US$8.20
+600.85%
36.09%US$14.00US$3.00n/a10
May ’26US$1.69
US$9.18
+443.30%
35.31%US$14.00US$3.00n/a11
Apr ’26US$1.37
US$9.18
+570.21%
35.31%US$14.00US$3.00n/a11
Mar ’26US$1.95
US$9.23
+373.19%
35.60%US$14.00US$3.00n/a11
Feb ’26US$1.80
US$9.23
+412.63%
35.60%US$14.00US$3.00n/a11
Jan ’26US$2.13
US$9.23
+333.21%
35.60%US$14.00US$3.00n/a11
Dec ’25US$2.48
US$9.04
+264.58%
35.44%US$14.00US$3.00n/a12
Nov ’25US$2.72
US$9.19
+237.90%
35.82%US$14.00US$3.50n/a11
Oct ’25US$2.67
US$9.28
+247.63%
33.87%US$14.00US$4.50US$1.2411
Sep ’25US$2.63
US$9.28
+252.92%
33.87%US$14.00US$4.50US$1.1311
Aug ’25US$2.74
US$11.24
+310.16%
67.79%US$35.00US$4.50US$1.0813
Jul ’25US$2.33
US$11.24
+382.34%
67.79%US$35.00US$4.50US$1.1813
Jun ’25US$2.50
US$11.24
+349.54%
67.79%US$35.00US$4.50US$1.1713
May ’25US$2.92
US$11.66
+299.26%
67.34%US$35.00US$4.40US$1.6912
Apr ’25US$4.38
US$11.66
+166.17%
67.34%US$35.00US$4.40US$1.3712
Mar ’25US$4.94
US$11.67
+136.17%
67.23%US$35.00US$4.50US$1.9512
Feb ’25US$3.71
US$11.75
+216.71%
66.46%US$35.00US$4.50US$1.8012
Jan ’25US$3.21
US$13.13
+309.14%
53.88%US$35.00US$4.50US$2.1315
Dec ’24US$2.52
US$13.57
+438.55%
52.51%US$35.00US$4.50US$2.4814
Nov ’24US$2.83
US$16.71
+490.61%
51.79%US$35.00US$5.00US$2.7214
Oct ’24US$3.17
US$16.86
+431.77%
50.78%US$35.00US$5.00US$2.6714
US$7.56
Fair Value
82.4% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 11:51
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allogene Therapeutics, Inc. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Shanshan XuBerenberg
Jason Matthew GerberryBofA Global Research